These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 26034039)

  • 1. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
    McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
    Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
    Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
    Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
    Belum VR; Wu S; Lacouture ME
    Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.
    Melosky BL; Lim HJ; Davies JM; Gill S; Kollmannsberger CK; Ho MY; Vandt SA; Renouf DJ
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):411-417. PubMed ID: 30535909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
    Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
    Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
    Jatoi A; Ou FS; Ahn DH; Zemla TJ; Le-Rademacher JG; Boland P; Ciombor KK; Jacobs NL; Pasche B; Cleary JM; McCune JS; Pedersen KS; Barzi A; Chiorean EG; Heying EN; Lenz HJ; Sloan JA; Grothey A; Lacouture ME; Bekaii-Saab T
    Oncologist; 2021 Jul; 26(7):610-618. PubMed ID: 33604969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
    Manchen E; Robert C; Porta C
    J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.
    Grothey A; George S; van Cutsem E; Blay JY; Sobrero A; Demetri GD
    Oncologist; 2014 Jun; 19(6):669-80. PubMed ID: 24821824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management.
    Ai L; Xu Z; Yang B; He Q; Luo P
    Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1121-1127. PubMed ID: 31679411
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.
    Ono K; Murase R; Matsumoto N; Kubota Y; Ishida H; Fujita KI
    Cancer Chemother Pharmacol; 2024 Jul; 94(1):57-66. PubMed ID: 38459188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to a topical moisturizing preparation for regorafenib-related hand-foot skin reaction.
    Sato J; Ishikawa H; Hamauchi S; Yamawaki Y; Mori K; Kiyohara Y; Yoshikawa S; Yamazaki K; Yasui H; Shino M
    J Oncol Pharm Pract; 2020 Mar; 26(2):361-367. PubMed ID: 31106665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
    Belum VR; Serna-Tamayo C; Wu S; Lacouture ME
    Clin Exp Dermatol; 2016 Jan; 41(1):8-15. PubMed ID: 26009777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
    Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
    J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
    Pandy JGP; Franco PIG; Li RK
    Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
    Balagula Y; Wu S; Su X; Feldman DR; Lacouture ME
    Invest New Drugs; 2012 Aug; 30(4):1773-81. PubMed ID: 21394443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).
    Anderson R; Jatoi A; Robert C; Wood LS; Keating KN; Lacouture ME
    Oncologist; 2009 Mar; 14(3):291-302. PubMed ID: 19276294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.